ArticleBMC bioinformatics2009
Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior.
Article in BMC bioinformatics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed.
- Calibrating T cell responsiveness through interactions with self.Nature reviews. Immunology · 2026Review
- AI-driven neoantigen identification: a comprehensive review from somatic variant calling to T cell recognition.Journal of translational medicine · 2026Review
- Automating neoantigen selection for personalized cancer vaccine design.medRxiv : the preprint server for health sciences · 2026Article
- TransBindpMHCI: a transformer-based model for pan-specific MHC-I peptide binding prediction.BMC bioinformatics · 2026Article
- Quantifying Cross-Attention Interaction in Transformers for Interpreting TCR-pMHC Binding.ArXiv · 2026Article
- Integration of Short- and Long-Read RNA Sequencing Enables the Discovery of Circular RNAs.Cancer research · 2026Article
- Multimodal learning on heterogeneous subgraphs and LLMs representation for MHC-peptide binding affinity prediction.BMC bioinformatics · 2026Article
- A Framework for Comparing Mouse Neoantigen Immunogenicity.bioRxiv : the preprint server for biology · 2026Article
- NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes.Nature communications · 2026Article
- CD8 co-receptor modulates the specificity profile of the 1G4 TCR against NY-ESO-1.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Identification of tumor-associated antigens with multi-cancer therapeutic potential.Frontiers in immunology · 2026Article
- Article
- Comparative analysis of pan MHC‑I epitopes immunoreactivity on Hantaan virus nucleocapsid protein.International journal of molecular medicine · 2026Article
- Integrated immunoreactivity analysis of MHC-I epitopes derived from the Marburg virus glycoprotein.Frontiers in immunology · 2026Article
- Article
- Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates.NPJ vaccines · 2025Article
- SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics.Genome medicine · 2025Article
- Characterization of Tumor Antigens from Multi-omics Data: Computational Approaches and Resources.Genomics, proteomics & bioinformatics · 2025Review
- Computational methods and data resources for predicting tumor neoantigens.Briefings in bioinformatics · 2025Review
- Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review).International journal of oncology · 2025Review
80 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundExperts in peptide:MHC binding studies are often able to estimate the impact of a single residue substitution based on a heuristic understanding of amino acid similarity in an experimental context. Our aim is to quantify this measure of similarity to improve peptide:MHC binding prediction methods. This should help compensate for holes and bias in the sequence space coverage of existing peptide binding datasets.
resultsHere, a novel amino acid similarity matrix (PMBEC) is directly derived from the binding affinity data of combinatorial peptide mixtures. Like BLOSUM62, this matrix captures well-known physicochemical properties of amino acid residues. However, PMBEC differs markedly from existing matrices in cases where residue substitution involves a reversal of electrostatic charge. To demonstrate its usefulness, we have developed a new peptide:MHC class I binding prediction method, using the matrix as a Bayesian prior. We show that the new method can compensate for missing information on specific residues in the training data. We also carried out a large-scale benchmark, and its results indicate that prediction performance of the new method is comparable to that of the best neural network based approaches for peptide:MHC class I binding.
conclusionA novel amino acid similarity matrix has been derived for peptide:MHC binding interactions. One prominent feature of the matrix is that it disfavors substitution of residues with opposite charges. Given that the matrix was derived from experimentally determined peptide:MHC binding affinity measurements, this feature is likely shared by all peptide:protein interactions. In addition, we have demonstrated the usefulness of the matrix as a Bayesian prior in an improved scoring-matrix based peptide:MHC class I prediction method. A software implementation of the method is available at: http://www.mhc-pathway.net/smmpmbec.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.